Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738469 | 0.90 | NR1H2 (0.44) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL22276814 | 0.90 | CHRM2 (0.47) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL20210116 | 0.90 | CHRM2 (0.48) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL737422 | 0.87 | NR1H2 (0.46) | CHRM2CHRM1CHRM3NR1H2DDB1 | |
| SCHEMBL15437639 | 0.87 | CHRM2 (0.50) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL15437638 | 0.87 | CHRM2 (0.50) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL23658362 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL413300 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL13931011 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL23658364 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | SUANZHU PHARMA CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | SUANZHU PHARMA CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| EP-3281942-A1 | B-LACTAMASE INHIBITOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3281942-A1 | B-LACTAMASE INHIBITOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-02-14 | — | — | EP | disclosed |
| WO-2017167218-A1 | ANTIBACTERIAL COMPOSITION AND USE THEREOF | 山东轩竹医药科技有限公司 | 2017-10-05 | — | — | WO | disclosed |
| WO-2017045510-A1 | Β-LACTAMASE INHIBITOR AND APPLICATION THEREOF | 山东轩竹医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090306123-A1 | Bicyclononene derivaties | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1786814-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | MGAM, LCT, ALPI | CHRM2 1055/4885CHRM1 609/4885CHRM3 2234/4885 |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | MGAM, LCT, ALPI | CHRM2 1084/4885CHRM1 623/4885CHRM3 2238/4885 |
| US-20090306123-A1 | Bicyclononene derivaties | REN, ACE, CYP51A1 | CHRM2 2876/4885CHRM1 2220/4885CHRM3 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.